Genetic Correlates of Phenotypic Variability in c.5882G>A p.(Gly1961Glu)-Associated Stargardt Disease
Investigative Ophthalmology & Visual Science · 12.02.2026 · 67 (2) · 32
DOI: 10.1167/iovs.67.2.32 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Investigative Ophthalmology & Visual Science, erschienen am 12.02.2026. Verfasst von Jeroen A A H Pas und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Radboud University Medical Center, Nijmegen, the Netherlands. Hauptthemen laut MEDLINE: ATP-Binding Cassette Transporters, Macular Degeneration. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Purpose
To quantitatively investigate disease progression and genotype-phenotype correlations in Stargardt disease patients harboring the common ABCA4 variant c.5882G>A p.(Gly1961Glu), aiming to evaluate the contribution of second ABCA4 variants to disease severity.
Methods
This multicenter study included 77 Stargardt disease patients uniformly carrying the ABCA4 c.5882G>A p.(Gly1961Glu) variant from Nijmegen, Bonn, and Basel. Ellipsoid zone (EZ) loss was measured using automated segmentation of optical coherence tomography images. Progression was assessed with linear mixed-effects models. Disease severity was quantified by the age-at-criterion EZ loss, defined as the estimated age when EZ atrophy reached 6.25 mm², allowing a comparison of the effects of different second alleles.
Results
A total of 52 patients were included in the study. The median age at first observation was 41 years (interquartile range, 27-52 years). The median age at criterion EZ loss across all patients was 43 years (interquartile range, 31-51 years). Substantial variability in the progression of EZ loss was observed among patients despite the shared c.5882G>A p.(Gly1961Glu) genotype. Differences in specific second ABCA4 variants were strongly associated with variation in disease progression, with some variants linked to markedly earlier progression (e.g., c.1957C>T, -50.7 years) and others associated with delayed progression (e.g., c.1648G>A, +19.8 years).
Conclusions
The ABCA4 c.5882G>A p.(Gly1961Glu) variant is associated with substantial interpatient variability in disease severity, heavily influenced by the nature of the second ABCA4 allele. These findings highlight the importance of precise genotypic characterization in prognostic counseling, clinical trial stratification, and the design of targeted gene therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Ophthalmology, Radboud University Medical Center, Nijmegen, the Netherlands.
- Donders Institute for Brain, Cognition and Behaviour, Nijmegen, the Netherlands.
- Department of Ophthalmology, University of Bonn, Bonn, Germany.
- Department of Ophthalmology, University of Basel, Basel, Switzerland.
- GRADE Reading center, Bonn, Bonn, Germany.
Zitieren
APA
Pas, J. A. A. H., Künzel, S. H., Ansari, G., Pfau, K., Chang, P., Herrmann, P., Holz, F. G., Hoyng, C. B., & Pfau, M. (2026). Genetic Correlates of Phenotypic Variability in c.5882G>A p.(Gly1961Glu)-Associated Stargardt Disease. Investigative Ophthalmology & Visual Science, 67(2), 32. https://doi.org/10.1167/iovs.67.2.32
Vancouver
Pas JAAH, Künzel SH, Ansari G, Pfau K, Chang P, Herrmann P, et al. Genetic Correlates of Phenotypic Variability in c.5882G>A p.(Gly1961Glu)-Associated Stargardt Disease. Investigative Ophthalmology & Visual Science. 2026;67(2):32. doi:10.1167/iovs.67.2.32
BibTeX
@article{Pas2026,
author = {Pas, Jeroen A A H and Künzel, Sandrine H and Ansari, Georg and Pfau, Kristina and Chang, Petrus and Herrmann, Philipp and Holz, Frank G and Hoyng, Carel B and Pfau, Maximilian},
title = {Genetic Correlates of Phenotypic Variability in c.5882G>A p.(Gly1961Glu)-Associated Stargardt Disease},
journal = {Investigative Ophthalmology & Visual Science},
year = {2026},
volume = {67},
number = {2},
pages = {32},
doi = {10.1167/iovs.67.2.32}
}
EUVIMED